BI 425809 clinical trials
Also written Iclepertin and BI 425809.
How each study uses BI 425809 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 28 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BI 425809 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02342717Written as BI 425809How we know
- Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809CompletedPhase 1Boehringer IngelheimNCT02068690Written as BI 425809 PfOSHow we know
- Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)CompletedPhase 1Boehringer IngelheimNCT02337283Written as BI 425809How we know
- A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the BloodCompletedPhase 1Boehringer IngelheimNCT05613777Written as IclepertinHow we know
- A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT05076409Written as BI 425809How we know
- Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809CompletedPhase 1Boehringer IngelheimNCT02362516Written as BI 425809How we know
- A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT03817476Written as iCF1(T1) 25 milligram BI 425809How we know
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT05731895Written as IclepertinHow we know
- A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT05347004Written as BI 425809How we know
- Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and DigoxinCompletedPhase 1Boehringer IngelheimNCT02783040Written as BI 425809How we know
- A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTerminatedPhase 3Boehringer IngelheimNCT05211947Written as IclepertinHow we know
- A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT05723874Written as BI 425809How we know
- A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the BloodCompletedPhase 1Boehringer IngelheimNCT05258110Written as iclepertin (BI 425809)How we know
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney ProblemsCompletedPhase 1Boehringer IngelheimNCT05718843Written as BI 425809How we know
- Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02383888Written as BI 425809How we know
- A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT03082183Written as BI 425809How we know
- A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the BodyCompletedPhase 1Boehringer IngelheimNCT03654170Written as BI 425809 mixed with [C-14] BI425809How we know
- A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a TabletCompletedPhase 1Boehringer IngelheimNCT03783000Written as BI 425809How we know
- CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaCompletedPhase 3Boehringer IngelheimNCT04860830Written as IclepertinHow we know
- Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)CompletedPhase 3Boehringer IngelheimNCT04846881Written as IclepertinHow we know
Codes
What other systems call BI 425809 · ClinicalTrials.gg INT001170
- MeSH (NLM) C000634404BI 425809One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634404 | BI 425809 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.